Deep Medical Completes Series A Financing to Accelerate Clinical Trials and Market Expansion for its Microsurgery Robot

Recently, Guangzhou Deep Medical Technology Co., Ltd. (“Deep Medical”) announced the completion of its Series A financing, with the investment coming from healthcare-specialized fund Kangjun Capital. Following this round, Deep Medical will further advance the clinical trials, registration, and domestic and international market expansion for its microsurgery robot products.

Public information reveals that Qiangyun Capital acted as the exclusive financial advisor for this financing round and will be responsible for subsequent financing efforts.

This financing round also reflects the capital market’s continued interest in the fields of intelligent microsurgery equipment and surgical robotics. As products gradually move from technological R&D to clinical validation and registration, the microsurgery robot is becoming a noteworthy sub-sector within the medical robotics industry.

1. Deep Medical Focuses on Microsurgery Robots

Deep Medical is a medical device company specializing in the research, development, and clinical application of microsurgery robots. Its core product is the FUNZAR microsurgery robot.

According to public data, Deep Medical is committed to creating intelligent equipment that covers the full range of microsurgical procedures. The goal is to reduce the operational difficulty of microsurgery and improve operational stability and precision through robotics technology.

Microsurgery typically places high demands on a surgeon’s precision, stability, and endurance. Many fields, including hand surgery, plastic surgery, neurosurgery, and ophthalmology, involve microsurgical scenarios, giving microsurgery robots the potential for cross-specialty applications.

Public reports indicate that the FUNZAR microsurgery robot entered the clinical validation stage in December 2024 and is currently advancing clinical trial enrollment for multiple indications and surgical procedures in several hospitals.

2. FUNZAR Enters Multi-Center Clinical Advancement Stage

Moving from product R&D to clinical validation is a crucial stage for medical robots to transition from a technical product to a commercial one.

According to public reports, clinical trials for FUNZAR have been launched in hospitals in Beijing, Shanghai, Changsha, and Guangzhou, with clinical enrollment for multiple indications and surgical procedures underway.

In the 3rd China Microsurgery Association Super-Microsurgical Anastomosis Skills Competition held in 2025, a competition between a microsurgery robot and a surgeon performing manual anastomosis was included for the first time. Public reports show that FUNZAR was the selected device for the robot group and completed high-precision micro-operations such as end-to-end anastomosis of a mouse tail artery.

Such clinical and academic scenarios provide a practical basis for microsurgery robots to further validate product performance and explore clinical application scenarios.

It should be noted that the specific clinical effects, registration progress, and commercial performance of the product should be based on information subsequently disclosed by regulatory authorities, clinical trials, and the company.

3. From “Microscope” to “Microsurgery Robot”

One of the core features of microsurgery is the high requirement for operational scale and precision.

Traditional microsurgery primarily relies on surgeons observing the surgical area through a microscope and performing operations with fine instruments. A robotic system, under the surgeon’s control, can introduce mechanical systems, vision systems, and precision motion control technology into the micro-operation process.

Deep Medical states that its product aims to solve clinical problems in microsurgery such as high operator intensity and high precision requirements, and to improve operational stability and precision through robotics technology.

According to public information, FUNZAR adopts a modular, universal design and explores a “universal platform + specialty consumables” product model.

The core of this product idea is: based on a universal robot platform, develop corresponding products or consumables for different specialties and surgical procedures, thereby covering more microsurgical application scenarios.

4. Capital to Further Support Clinical, Registration, and Commercialization Push

For innovative medical device companies, once they move from the R&D stage to the clinical registration stage, their funding needs typically expand from pure product R&D to include:

• Clinical registration trials;
• Product registration;
• Clinical application in hospitals;
• Construction of production systems;
• Market access;
• Building a commercialization team;
• Domestic market expansion;
• Overseas market expansion.

Therefore, for Deep Medical, this Series A financing not only signifies capital support during the R&D phase but also means the company is beginning to further advance the clinical and commercial implementation of its product.

Investor Kangjun Capital stated that it is optimistic about the strategic value of universal microsurgery robots and recognizes Deep Medical’s medical-engineering cross-disciplinary team, as well as FUNZAR’s technical architecture and product design. Kangjun Capital also indicated that it will continue to support the company in advancing clinical trials and commercialization.

5. Microsurgery Robotics is Still in an Industrial Development Stage

Globally, microsurgery robotics is still a relatively new sub-field of medical robotics.

Public industry reports mention that approved microsurgery robot products have already appeared on the international market, including Symani in the United States and MUSA in the European market.

At the same time, microsurgery covers multiple specialties such as hand surgery, plastic surgery, neurosurgery, and ophthalmology. Product development needs to simultaneously solve multiple problems including robotic precision motion, clinical needs, surgeon operating habits, surgical workflow, and medical device registration.

Therefore, for microsurgery robot companies, technological R&D is only part of the industrialization process.

From a long-term commercialization perspective, companies also need to continuously address the entire chain:

Clinical Value → Registration Approval → Hospital Application → Physician Training → Market Access → Commercial Promotion

6. From Technological Innovation to the International Market

After this round of financing, Deep Medical plans to further promote its domestic and international market expansion.

For high-end medical devices like microsurgery robots, internationalization typically requires simultaneous consideration of the different countries’ and regions’:

• Medical device regulatory requirements;
• Clinical evaluation systems;
• Hospital procurement systems;
• Physician usage habits;
• Distributor and commercialization channels;
• Localized after-sales service;
• Intellectual property protection;
• Market access policies.

Therefore, expanding into overseas markets is not just about selling products abroad but requires establishing an internationalization strategy that matches the regulatory, clinical, and commercial systems of the target market.

For Chinese medical device companies with technological innovation capabilities, models such as licensing, strategic partnerships, overseas distribution, joint development, and industrial cooperation may also become important tools for future international BD.

The specific model to adopt needs to be determined based on the product’s registration status, intellectual property, target market, partner capabilities, and the company’s own commercialization resources.

7. The Value Chain of the Medical Robotics Industry is Continuously Extending

From an industry perspective, a medical robot is not a single software or hardware product, but a comprehensive system involving multiple technologies and industrial capabilities.

Its value chain may include:

Core Technology R&D → Robot System → Medical Device Registration → Clinical Application → Specialty Consumables → Hospital Channels → Commercialization Services → International Market

Therefore, the future competition for medical robotics companies will not only be reflected in the robot itself but may also extend to:

• Core technology;
• Patent layout;
• Clinical resources;
• Collaboration with physicians;
• Registration capabilities;
• Product portfolio;
• Specialty consumables;
• Commercialization capabilities;
• Overseas market expansion capabilities.

For investment institutions and industrial capital, this also means that when evaluating medical robotics companies, the assessment needs to extend from a single product evaluation to the company’s overall industrialization capabilities.

8. Industry Observation: Clinical Value Remains the Core of Medical Robot Commercialization

Surgical robots ultimately serve clinical scenarios.

Therefore, for innovative medical devices like microsurgery robots, technical parameters do not fully represent commercial value. Companies also need to prove that their product can solve clear problems in real clinical scenarios and form a sustainable product and business model.

From the perspective of the industry’s development path, we can focus on the following stages:

1. Technical Feasibility

Can the robot achieve the target precision, stability, and control capabilities.

2. Clinical Feasibility

Can the product meet the actual needs of doctors and patients.

3. Registration Feasibility

Can the product complete clinical evaluation and registration according to regulatory requirements.

4. Commercial Feasibility

Do hospitals have a clear procurement and usage demand.

5. Scalability Feasibility

Can the product be promoted on a large scale through a standardized platform, specialty products, and a consumables system.

These stages together determine the process of an innovative medical robot moving from laboratory technology to industrialization.

Conclusion

After completing its Series A financing, Deep Medical will further advance the clinical trials, registration, and domestic and international market expansion of its FUNZAR microsurgery robot.

From an industry perspective, the microsurgery robot is in a stage where technological innovation, clinical validation, and commercial exploration are proceeding in parallel. For medical device companies, industrial capital, and investment institutions, what will be worth watching in the future is not only individual robotic technology breakthroughs but also clinical value validation, registration progress, specialty application expansion, business models, and international market layout.

As medical robotics technology continues to enter more refined clinical scenarios, how to transform robotic technology into verifiable clinical value and further establish a sustainable commercialization model will become a key topic for the continued development of this sub-field.

Related Information

Company: Guangzhou Deep Medical Technology Co., Ltd. Core Product: FUNZAR Microsurgery Robot Financing Round: Series A Investor: Kangjun Capital Exclusive Financial Advisor: Qiangyun Capital Key Focus Areas: Microsurgery robots, medical devices, clinical applications, registration, and domestic/international market expansion

Note: This article is compiled based on public information and is for industry information and observation purposes only. It does not constitute investment advice. Information regarding corporate financing, product clinical trials, and registration is subject to subsequent public disclosures by the relevant companies and regulatory agencies.

FAQ

What financing round did Deep Medical just complete?

Public information shows that Guangzhou Deep Medical Technology Co., Ltd. announced the completion of its Series A financing in February 2026, with the investment from Kangjun Capital.

What is Deep Medical’s core product?

Deep Medical’s core product is the FUNZAR microsurgery robot, positioned for microsurgical scenarios, and is advancing clinical applications and registration work for multiple indications and procedures.

What stage is the FUNZAR microsurgery robot currently in?

Public data indicates that FUNZAR entered the clinical validation stage in December 2024 and is currently advancing clinical trials and enrollment for multiple indications or procedures in hospitals in Beijing, Shanghai, Changsha, and Guangzhou.

What will Deep Medical’s latest financing be used for?

Public information states that after this financing round, Deep Medical will further accelerate clinical trials, registration, and domestic and international market expansion.

What main problems do microsurgery robots solve?

Microsurgery robots are primarily aimed at clinical scenarios in microsurgery that require high precision, stability, and fine motor skills. Deep Medical states that its product goals include reducing the difficulty of microsurgery and improving operational stability and precision.